Late-Life Semaglutide Extends Female Mice Lifespans by About 12 Percent, Nature Study Finds

A widely used obesity and diabetes drug has shown it can slow aging and extend lifespan when given late in life to older female mice, adding weight to the idea that GLP-1 medicines may do more than manage metabolic disease. A study published in Nature on September 2, 2026, led by Danica Chen's laboratory at the University of California, Berkeley, found that 20-month-old female mice treated with semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, lived a median of 834 days compared with 742 days for control animals, a gain of about 12 percent that was achieved when treatment began at an age roughly equivalent to 60 to 65 human years. The National Institutes of Health, which funded the work, said in a September 2 release that the results support the idea that GLP-1 receptor activation can act as a calorie-restriction mimetic with benefits that extend beyond weight loss.

The study lands at a moment when GLP-1 drugs are already reshaping medicine and when researchers are asking whether their effects on inflammation, cellular maintenance and metabolism translate into slower aging itself. What makes the Berkeley result notable is that the mice were not obese and did not have age-related disease at the start of treatment, which means the lifespan gain was not simply a correction of metabolic illness but something closer to a genuine slowing of the aging process. News-Medical reported on Sep 3 that the treated mice also showed better muscle function, motor coordination, spatial memory and insulin sensitivity than controls, a pattern of broad physiological improvement rather than a single metabolic effect.

Key Facts

The experimental design was built to isolate aging effects from weight-loss effects. The researchers treated 20-month-old female mice with semaglutide or a saline control, either for three months or until the end of life, and because semaglutide reduced food intake by about 24 percent, they added a matched group that received a 24 percent calorie-restricted diet, according to the Nature paper published on September 2. The comparison is the crux of the study, because it tests whether semaglutide simply makes animals eat less or whether it activates biology that calorie restriction does not. The paper reported that outcomes were largely similar between the drug group and the calorie-restricted group, which supports the interpretation that semaglutide works at least in part as a calorie-restriction mimetic.

The results also showed differences that favored the drug. NIH reported on September 2 that semaglutide-treated mice surpassed the calorie-restricted group in exploratory behavior, spatial memory and blood-sugar maintenance, and that while calorie-restricted mice showed a reduced metabolic rate, semaglutide-treated mice maintained a normal metabolic rate even as they ate roughly a quarter less. That combination, fewer calories consumed without the metabolic slowdown that usually accompanies dietary restriction, is the kind of finding that makes researchers think GLP-1 drugs may engage pathways that restriction alone does not fully capture. The study also reported reductions in hallmark signs of aging, including genomic instability, chronic inflammation, cellular senescence and mitochondrial dysfunction, along with increased neural stem cell activity in the hippocampus.

The magnitude of the lifespan effect is meaningful in context. The median survival gain from 742 to 834 days is roughly 92 days, or about 12.4 percent, and it came from treatment that began only in late life, not from lifelong dosing, which News-Medical reported on Sep 3 makes the effect unusually large for an intervention started so late. For comparison, many longevity interventions in mice produce their largest effects when started young, so a double-digit lifespan extension from a late-life start is the kind of result that pushes a drug toward human aging trials. The caveats are equally clear, the study used a single mouse strain and only females, and the authors and outside experts emphasized that mouse longevity does not translate directly to human lifespan.

Analysis

What this really means is that the GLP-1 drug class, already the most commercially important pharmaceutical development of the decade, is accumulating evidence that it may slow biological aging rather than merely treat its downstream diseases, and that distinction has enormous implications for how these drugs will be studied, priced and prescribed. If semaglutide extends life partly through mechanisms independent of calorie restriction, as the metabolic-rate finding suggests, then its value extends far beyond the obesity and diabetes markets that have made Novo Nordisk and Eli Lilly the most valuable drug companies in the world. The bigger picture here is that the pharmaceutical industry has spent decades trying and failing to develop a credible anti-aging drug, and the GLP-1 class may have stumbled into that territory by accident, which would make the longevity indication the next great battleground for a drug class already struggling with supply and affordability.

The calorie-restriction comparison is the most scientifically important part of the study, because it addresses a question that has divided the field for years. Calorie restriction is the most reproducible lifespan-extending intervention in animal models, but it has never been a practical human therapy, because sustained dietary restriction is extremely difficult to maintain. If a drug can reproduce the benefits of calorie restriction while preserving metabolic rate and improving cognition beyond what restriction alone achieves, it offers a pharmacological route to an intervention that has otherwise been confined to the laboratory. The finding that semaglutide-treated mice outperformed calorie-restricted mice on memory and exploratory behavior, reported by NIH on September 2, is particularly interesting, because it hints that GLP-1 signaling in the brain, where the drugs are known to act on appetite circuits, may have effects on neural function that starvation-like states do not reproduce.

The path from this study to human relevance is long and uncertain, and it is worth being precise about what the result does not show. The mice were genetically uniform females of a single strain, and the human equivalent of a 12 percent lifespan extension from late-life treatment is not established by any current data. Long-term trials in older humans would take years and would need to separate any longevity effect from the drugs' known benefits on cardiovascular disease, which is itself a major cause of death and would confound any lifespan signal. The realistic read is that this study strengthens the case for investing in those trials, not that it proves semaglutide will extend human life, and the commercial stakes are so large that the pharmaceutical industry will almost certainly fund the research needed to find out.

Why It Matters

For the GLP-1 drug market, the study adds a longevity narrative to a class already projected to generate tens of billions of dollars in annual sales, and it will intensify competition between Novo Nordisk, which owns semaglutide, and the rivals that are racing it in the GLP-1 market to run the aging trials that could unlock a new indication. For the aging-research field, the result validates the calorie-restriction-mimetic hypothesis with a drug that is already approved and widely prescribed, which removes one of the biggest barriers to translating longevity research, the lack of a regulatory path for a drug that has no single disease target. For regulators, the study raises a question that the FDA has not yet answered, how to evaluate a drug whose primary benefit may be the slowing of aging rather than the treatment of a specific condition. And for patients, the finding is a reminder that the drugs millions of people already take for diabetes and obesity may have effects on the aging process itself, which will only intensify the debate about who should take GLP-1 medicines and who should pay for them.

Next Up

In the coming weeks, watch for follow-up analyses from the Berkeley group on the mechanisms that distinguish semaglutide from calorie restriction, since the metabolic-rate difference is the most promising lead toward a distinct anti-aging pathway. Watch also for whether Novo Nordisk or academic collaborators announce plans for longer-term studies in older animals, including male mice and additional strains, which would address the most obvious limitations of the current result. The most important signal will come from the human side, where ongoing GLP-1 cardiovascular trials may already be collecting the kind of long-term mortality data that could hint at whether the longevity effect extends beyond mice; if those trials show all-cause mortality benefits, the case for dedicated human aging studies will become very difficult to ignore.